NCT07281768招募中2 期
Combining Capecitabine/Oxaliplatin Chemotherapy With Cemiplimab Alone or in Combination With Fianlimab or REGN7075 for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2026年7月14日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Pathologic complete response (pCR) rate
研究概览
简要总结
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-positive, T3 node-negative, T3 node-positive).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 -
- •Rectal cancer (with tumor tissue present at or below the peritoneal reflection) as determined by MRI pelvis or endoscopic ultrasound.
- •Have histologically proven mismatch repair proficient (pMMR) or microsatellite stable (MSS) rectal adenocarcinoma.
- •Must not have received any prior systemic treatment or radiation.
- •Candidate for sphincter-sparing surgical resection after neoadjuvant therapy according to the primary surgeon.
- •Patients have the following clinical staging:
- •cT2 node-positive:
- •T: Tumor is invading the muscularis propria but has not grown through it to the serosa
- •N: At least 1 perirectal lymph node ≥5 mm and no more than 4 perirectal lymph nodes >10 mm in short axis
- •M: No evidence of metastasis
- •cT3 node-negative
- •T: Tumor has grown through the muscularis propria into the serosa but has not invaded nearby organs
- •N: No perirectal lymph nodes ≥ 5 mm in size that suggest tumor involvement
- •M: No evidence of metastasis
- •cT3 node-positive
- •T: Tumor has grown through the muscularis propria into the serosa but has not invaded nearby organs
- •N: At least 1 perirectal lymph node ≥ 5 mm and no more than 4 perirectal lymph nodes > 10 mm in size in short axis
- •M: No evidence of metastasis
- •Absence of distant metastases on CT or MRI imaging
- •Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
- •LVEF assessment with documented LVEF ≥ 50% by either TTE or MUGA (TTE preferred) within 6 months from first study drug administration.
- •For both Women and Men, must use acceptable form of birth control while on study.
- •Ability to understand and willingness to sign a written informed consent document.
排除标准
- •Have received an investigational agent or used an investigational device within 28 days of the first dose of study drug.
- •Have expected to require any other form of systemic or localized antineoplastic therapy while on study.
- •Have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.).
- •History of prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies for any reason.
- •Currently using any chronic systemic steroids.
- •History of severe hypersensitivity reaction to any monoclonal antibody.
- •History of encephalitis, meningitis, dementia, Parkinson's or uncontrolled seizures within 1 year prior to the first dose of study drug.
- •Uncontrolled infection of HIV, HBV, HCV, or Tuberculosis.
- •Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Active autoimmune disease.
- •Any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft.
- •Patient has a pulse oximetry of <92% on room air.
- •Patient is on supplemental home oxygen.
- •Has clinically significant heart disease.
- •Troponin T (TnT) or troponin I (TnI) > 2x institutional ULN at baseline.
- •Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.
- •Patient is pregnant or breastfeeding.
- •Unwilling or unable to follow the study schedule for any reason.
- •Patient received a live vaccine within 30 days of planned start of study medication.
- •Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.
- •Patients with T4 disease or N2 disease (as defined by >/= 4 lymph nodes, each greater or equal to 10 mm in short axis).
- •Evidence that the tumor is adjacent to (defined as within 3 mm of) the mesorectal fascia on pre-operative MRI or endorectal ultrasound or pelvic CT scan.
- •Patients with symptomatic untreated bowel obstruction due to rectal cancer.
研究组 & 干预措施
Arm B (Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab)
Experimental
干预措施: Fianlimab (Drug)
Arm A (Oxaliplatin, Capecitabine, Cemiplimab)
Experimental
干预措施: Capecitabine (Drug)
Arm A (Oxaliplatin, Capecitabine, Cemiplimab)
Experimental
干预措施: Cemiplimab (Drug)
Arm B (Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab)
Experimental
干预措施: Cemiplimab (Drug)
Arm C (Oxaliplatin, Capecitabine, Cemiplimab, REGN7075)
Experimental
干预措施: Cemiplimab (Drug)
Arm B (Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab)
Experimental
干预措施: Oxaliplatin (Drug)
Arm A (Oxaliplatin, Capecitabine, Cemiplimab)
Experimental
干预措施: Oxaliplatin (Drug)
Arm B (Oxaliplatin, Capecitabine, Cemiplimab, Fianlimab)
Experimental
干预措施: Capecitabine (Drug)
Arm C (Oxaliplatin, Capecitabine, Cemiplimab, REGN7075)
Experimental
干预措施: Capecitabine (Drug)
Arm C (Oxaliplatin, Capecitabine, Cemiplimab, REGN7075)
Experimental
干预措施: Oxaliplatin (Drug)
Arm C (Oxaliplatin, Capecitabine, Cemiplimab, REGN7075)
Experimental
干预措施: REGN7075 (Drug)
结局指标
主要结局
Pathologic complete response (pCR) rate
时间窗: 24 months
Proportion of subjects with a pathologic complete response (pCR) at the time of surgery. pCR is defined as subjects with no viable tumor cell noted on pathological evaluation of the resection specimen using the College of American Pathologists (CAP) tumor regression scoring system (CAP tumor regression score of 0).
次要结局
- Number of participants experiencing grade 3 or above drug-related toxicities(12 weeks)
- Pathologic Response Rate(24 months)
- Event-free Survival (EFS)(24 months)
- Composite Complete Response Rate(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell CarcinomaNCT07281417National Cancer Institute (NCI)108
招募中
2 期
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.NSCLCNCT07264673Fondazione Ricerca Traslazionale160
招募中
2 期
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)2024-512652-38-00Replimune Group Inc.143
招募中
3 期
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)Cholangiocarcinoma2024-513513-12-00Incyte Corp.110
进行中（未招募）
不适用
Capecitabine in combination with Oxaliplatin, Irinotecan and Bevacizumab (COI-B regimen) as First-Line therapy for metastatic colorectal cancer: a Phase II I.T.M.O. study. - COI BPatients affected by colorectal carcinoma untreated with metastasisMedDRA version: 9.1Level: LLTClassification code 10025856Term: Malignant neoplasm of colon stage IVEUCTR2008-008749-39-ITI.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY